Exchange: NYSE·Updated 07:57 PM EDT

DHR News

News
all
press releases
Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?
Revvity's raised 2026 outlook, Diagnostics growth and stronger cash flow brighten the setup, but premium valuation and software risks call for selectivity.
Zacks
More News
Pediatrix Medical Group (MD) Up 3.4% Since Last Earnings Report: Can It Continue?
Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Danaher (DHR) Seen Deftly Navigating AI Integration
Danaher (DHR) Seen Deftly Navigating AI Integration...
Yahoo! Finance: News
Why Is Avantor (AVTR) Up 5.4% Since Last Earnings Report?
Avantor (AVTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Insider Transaction: Rainer Blair Sells $12.74M Worth Of Danaher Shares
Making a noteworthy insider sell on August 24, Rainer Blair, President & CEO at Danaher (NYSE:DHR), is reported in the latest SEC filing. What Happened: Blair's decision to sell 58,255 shares of Danaher wasread more...
Benzinga
Danaher Rides on Strength in Biotechnology Segment: Will It Sustain?
DHR's Biotechnology segment grows as China demand, bioprocessing and improving discovery markets offset regional headwinds.
Zacks
Here's What Is Shaping Abbott's Diagnostics Growth
ABT's Diagnostics growth is being reshaped as weaker respiratory testing offsets healthy routine demand and 13% cancer diagnostics growth.
Zacks
Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation?
BIO's digital PCR gains and recurring diagnostics base support growth, but a 40.2X forward P/E and muted 2026 outlook keep valuation risk in focus.
Zacks
QDEL's 2026 Outlook Cut Deepens China and Respiratory Risk Concerns
QuidelOrtho's 2026 outlook cut highlights deeper China and respiratory risks, while cash use and rising debt add pressure despite resilient core growth.
Zacks
Is QDEL Worth Buying as China Risks Clash With Resilient Core Growth?
QuidelOrtho's resilient core growth and $50 million cost plan offer support, but China weakness, cash use and heavy debt keep the near-term case cautious.
Zacks

Advertisement|Remove ads.